ModifiedBlue Cross Blue Shield - LouisianaPolicy 00329

Surgical Treatment of Snoring and Obstructive Sleep Apnea Syndrome

Defines coverage, investigational status, and patient selection criteria for surgical and minimally invasive procedures to treat snoring and obstructive sleep apnea (OSA) for members of Blue Cross and Blue Shield of Louisiana.

Policy Summary

PayerBlue Cross Blue Shield - Louisiana

PolicySurgical Treatment of Snoring and Obstructive Sleep Apnea Syndrome

Policy CodePolicy 00329

Change TypeMaterial update — investigational statement added for non‑Inspire hypoglossal nerve stimulationcoding added (C1889)

Effective Date04/01/2026

Next Review Date01/2027

Key ActionObtain prior authorization and document prior CPAP or oral appliance trial and medical necessity before seeking surgical coverage.

SourceLink

POLICY UPDATE CHANGES

Added a Note: Hypoglossal nerve stimulation with the Inspire U.S. FDA-approved device is addressed in Carelon Sleep Disorder Management clinical guidelines.

Added an investigational statement for hypoglossal nerve stimulation with U.S. FDA-approved devices other than Inspire (e.g., Genio system 2.1) for treatment of clinically significant OSA.

Add code effective 04/01/2026: C1889

AHI ≥15Adult OSA threshold

AHI ≥5 + symptomsAlternate adult threshold

Pediatric AHI ≥5Pediatric threshold

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

63.5%Genio trial response

Coverage Criteria and Evidence Summary

Surgical treatment (adults)

Covered when ALL of the following are met

Adult surgical candidates for palatopharyngoplasty: Appropriately selected adults with clinically significant obstructive sleep apnea (OSA) who have failed an adequate trial of continuous positive airway pressure (CPAP) or an adequate trial of an oral appliance (OA)see AHI/RDI/REI thresholds

Procedures include palatopharyngoplasty variants (e.g., UPPP, uvulopharyngoplasty, expansion sphincter pharyngoplasty, lateral pharyngoplasty, palatal advancement pharyngoplasty, relocation pharyngoplasty); other surgeries (hyoid suspension, tongue modification, mandibular-maxillary advancement) may be considered for hypopharyngeal obstruction with objective documentation

Hypopharyngeal/Maxillofacial procedures

Covered when ALL of the following are met

Hyoid suspension / tongue modification / maxillofacial surgery: Appropriately selected adults with clinically significant OSA and objective documentation of hypopharyngeal obstruction who have failed an adequate trial of CPAP or an adequate trial of an oral appliancesee AHI/RDI/REI thresholds

Mandibular-maxillary advancement (MMA) candidates typically require cephalometric x-rays and drug-induced sleep endoscopy (DISE) for preoperative evaluation

Pediatric adenotonsillectomy

Covered when ALL of the following are met

Adenotonsillectomy (pediatric): Pediatric individuals with clinically significant OSA and hypertrophic tonsilspediatric AHI/RDI thresholds

Pediatric thresholds: AHI or RDI ≥5 events/hour, or AHI or RDI ≥1.5 events/hour with excessive daytime sleepiness, behavioral problems, or hyperactivity

Procedure-specific evidence summaries

Summary of evidence-based stance by intervention:

Laser-assisted uvulopalatoplasty (LAUP): Systematic reviews and RCTs show modest mean AHI reduction, low success/cure rates, and notable complication rates; evidence is insufficient to determine net health benefit.

2019 systematic review (3,093 patients) reported ~26 complications per 100 LAUP-treated patients; most frequent complications: globus sensation (8%), dryness (7%), velopharyngeal insufficiency (4%).

Radiofrequency volumetric reduction (palate and base of tongue): Sham-controlled RCTs did not show benefit for single-stage RFA to the palate; multiple-session approaches and cohort studies show inconsistent or nonclinically significant AHI improvements; evidence insufficient to determine net health benefit.

Prospective cohort studies report short-term improvements but higher-quality RCT data are lacking.

Palatal stiffening procedures: Two sham-controlled RCTs with differing inclusion criteria produced mixed results; overall evidence is insufficient to determine net health benefit and further studies are needed to define appropriate selection criteria.

Investigational interventions

Policy contains eligible for coverage and investigational statements with criteria; specific numbered criteria are in other sections not included in this excerpt.

Investigational HNS (non-Inspire devices): Hypoglossal nerve stimulation with U.S. FDA-approved devices other than Inspire (e.g., Genio system 2.1) is investigational for treatment of clinically significant OSA.

Investigational statement added 01/05/2026; policy history documents changes and additions related to HNS and device-specific content.

The policy considers the following minimally invasive procedures investigational and not covered for the sole or adjunctive treatment of OSA or snoring without documented OSA: laser-assisted uvulopalatoplasty (LAUP) or radiofrequency volumetric tissue reduction of the palatal tissues; radiofrequency volumetric tissue reduction of the tongue (with or without palatal procedures); palatal stiffening procedures (including cautery-assisted palatal stiffening operation, sclerosing agent injection, and palatal implants); tongue base suspension; and all other minimally invasive procedures not specifically described.

Interventions intended to treat snoring alone (in the absence of documented OSA) are considered investigational and are not a covered medical condition under this policy; this includes procedures such as LAUP and palatal stiffening when criteria for OSA are not met.

This medical policy specifically does not address conventional surgical procedures such as uvulopalatopharyngoplasty (UPPP), hyoid suspension, surgical modification of the tongue, maxillofacial surgery, or adenotonsillectomy; those established surgical approaches are managed separately and are not the focus of the minimally invasive procedure coverage statements in this policy.

The policy states that snoring alone is not considered a medical condition; therefore, interventions for snoring without documented obstructive sleep apnea are investigational and not covered.

Surgical treatment of OSA that does not meet the policy's stated patient selection criteria (including the AHI/RDI/REI thresholds or documentation of failure/intolerance of CPAP or an adequate trial of an oral appliance) is considered not medically necessary and may be denied.

For LAUP, radiofrequency volumetric reduction (palate or tongue), palatal stiffening procedures, tongue base suspension, and Genio hypoglossal nerve stimulation, the available evidence is insufficient to determine that these technologies improve net health outcomes. The trials and reviews cited report modest or mixed AHI improvements, limited RCT data, and meaningful complication rates or study limitations, leading the Company to conclude that evidence does not currently support routine coverage outside the policy’s specific criteria or investigational context.

When the specific policy criteria are not met, related services are denied as not medically necessary. The policy history and coverage statements clarify that lack of documented eligibility (per the policy’s clinical thresholds and prior-therapy requirements) is a basis for medical necessity denial.

Procedure, Device and Diagnosis Coding

Device PMA/510(k) identifiers and relatedmixed

K982717	Radiofrequency ablation PMA/510(k)
K040417	Pillar palatal implant 510(k)
K122391	Tongue base suspension 510(k)
K111179	Tongue base suspension 510(k) (PRELUDE III)
P240024	Genio hypoglossal nerve stimulation PMA/510(k)

CPTCPT

0978T
0979T
0980T
21199
21685
31599
41512
41530
42120
42145

1–10 of 13

1/2

HCPCSHCPCS

C9727
S2080
C1889	Add code effective 04/01/2026

ICD-10 DiagnosisICD-10

G4733
G478
G479
R0683

AHI / RDI / REI thresholds — Adults and Pediatrics

Adult threshold (primary)AHI, RDI, or REI ≥ 15 events per hour

Adult threshold (with symptoms)AHI, RDI, or REI ≥ 5 events per hour PLUS excessive daytime sleepiness, unexplained hypertension, ischemic heart disease, or history of stroke

Pediatric threshold (primary)Pediatric AHI or RDI ≥ 5 events per hour

Pediatric threshold (with symptoms)Pediatric AHI or RDI ≥ 1.5 events per hour PLUS excessive daytime sleepiness, behavioral problems, or hyperactivity

AHI/RDI — CMS guidance and policy application

Authorization, Documentation, and Preoperative Requirements

Documentation Required

Coverage Contingent on Benefits and Medical Necessity

Coverage for surgical treatments and related services is contingent on benefits in the member's contract/certificate and meeting the policy's medical necessity criteria. If contract benefits are not available or medical necessity criteria are not met, the service is not eligible for coverage and may be denied as not medically necessary.

Coverage contingent on member contract and meeting medical necessity criteria
Denial = not medically necessary when criteria are not met

Prior Authorization

Device Implantation Prior Authorization

Prior authorization is required for implantation of implantable airway stimulation devices (for example, the Genio system) and other device implantation procedures when indicated by the member's plan. Confirm prior authorization requirements with the member's benefit plan before scheduling device implantation.

Clinical Background

Obstructive sleep apnea (OSA) is a syndrome characterized by repetitive episodes of upper airway obstruction during sleep, producing apneas and hypopneas. OSA is associated with daytime sleepiness and adverse cardiovascular and safety outcomes. Severity is commonly expressed using indices such as the Apnea–Hypopnea Index (AHI), Respiratory Disturbance Index (RDI), or Respiratory Event Index (REI), and established surgical approaches may be considered for individuals who have failed conservative therapy.

Definitions and Measurement Metrics

AHI — Apnea/Hypopnea Index definition and thresholds

DefinitionApnea–Hypopnea Index (AHI) = average number of apneas or hypopneas per hour of sleep

Adult severity categoriesMild: AHI 5 to <15 events/h; Moderate: AHI 15 to <30 events/h; Severe: AHI ≥30 events/h

Pediatric severity noteIn children, mild OSA AHI ≥1 to 5; moderate >5 to 10; severe >10 events/h

REI — Respiratory Event Index for home sleep studies

Definition (home studies)Respiratory Event Index (REI) = number of events per hour of monitoring time; used when EEG-derived sleep time is not available (typical of home sleep apnea testing)

Relation to AHI/RDIREI is used as an alternative to AHI or RDI for in-home studies and is incorporated into the policy selection criteria alongside AHI and RDI

Policy Summary

PayerBlue Cross Blue Shield - Louisiana

PolicySurgical Treatment of Snoring and Obstructive Sleep Apnea Syndrome

Policy CodePolicy 00329

Change TypeMaterial update — investigational statement added for non‑Inspire hypoglossal nerve stimulationcoding added (C1889)

Effective Date04/01/2026

Next Review Date01/2027

Key ActionObtain prior authorization and document prior CPAP or oral appliance trial and medical necessity before seeking surgical coverage.

SourceLink

On This Page

One trial reported 45% success in a selected subgroup; replication required.

Tongue base suspension: Evidence limited to a feasibility RCT (17 patients) comparing tongue suspension plus UPPP vs tongue advancement plus UPPP showing similar success; insufficient evidence to determine benefit of suspension alone.

Larger randomized trials are needed.

Hypoglossal nerve stimulation - Genio system: FDA approval based on a nonrandomized single-arm trial (DREAM) with 113 implanted patients demonstrated statistically significant reductions in AHI and ODI and improvements in secondary outcomes, but single-arm design, limited diversity, incomplete follow-up, and other limitations leave net health benefit uncertain.

Coprimary endpoints at 12 months: ≥50% reduction in 4% AHI with final AHI <20 (63.5% response) and ≥25% reduction in 4% ODI (71.3% response) among completers; 11 serious adverse events occurred in 10 (9%) patients.

CMS-adapted severity threshold

An AHI or RDI ≥ 15 events per hour identifies patients at increased risk of hypertension and is used to guide treatment decisions per CMS guidance

Lower-threshold treatment considerationFor AHI or RDI 5–14 events/hour, treatment may be warranted when associated symptoms (e.g., daytime somnolence) are present based on randomized trial data referenced by CMS

Policy useCMS definition of moderate-to-severe OSA was adapted for surgical management recommendations in this policy

RDI / REI definitions and addition to selection criteria

RDI definitionRespiratory Disturbance Index (RDI) = number of apneas, hypopneas, or respiratory event–related arousals per hour of sleep time; often used synonymously with AHI

REI definitionRespiratory Event Index (REI) = number of events per hour of monitoring time; used as an alternative to AHI or RDI in home sleep studies when EEG-derived sleep time is not available

Policy change noteRDI and REI were added to the patient selection criteria in prior updates to further define clinically significant OSA

Prior authorization likely required for Genio system implantation and similar devices
Confirm PA per member's contract

Step Therapy

First-line Therapy Requirement

Surgical management of OSA is typically considered only after failure of first-line therapy. Continuous positive airway pressure (CPAP) is the preferred first-line treatment for most individuals; oral appliances may be used as first-line for a smaller group. Surgery is considered when there is documented intolerance, failure, or inadequate adherence to CPAP or an adequate trial of an oral appliance.

CPAP is preferred first-line therapy; OA may be first-line for some patients
Surgery considered after failed/inadequate trial of CPAP or OA

Documentation Required

Clinical Justification and Prior PAP Documentation

Clinical justification must be documented in the medical record to support surgical coverage decisions. Documentation should include objective OSA severity (AHI, RDI, or REI), body mass index (BMI) where relevant, and clear evidence of failed, intolerant, or nonadherent trials of PAP or an oral appliance. For procedures addressing hypopharyngeal obstruction (e.g., MMA), include relevant preoperative evaluations such as cephalometric x-rays and drug-induced sleep endoscopy (DISE) when performed.

Document AHI/RDI/REI (e.g., ≥15 events/hr for moderate-to-severe OSA)
Document BMI when applicable and specifics of prior PAP or OA trial (duration, adherence, reasons for failure/intolerance)
Include DISE and cephalometric x-rays for MMA planning when available

Denial Risk

Risk of Denial if CMS Criteria or Prior CPAP Trial Not Documented

If documentation does not demonstrate CMS-adapted severity thresholds or an adequate prior CPAP (or OA) trial when applicable (for example, AHI/RDI ≥15 or documented intolerance/inadequate adherence), there is a risk the procedure will be denied as not medically necessary.

Risk of denial when CMS criteria for OSA severity or prior CPAP/OA trial are not documented
CMS guidance adapted for surgical consideration (AHI/RDI ≥15)

Prior Authorization

Authorization and Transition

Prior authorizations issued by a previous health plan for an ongoing course of treatment may be honored by Louisiana Blue for up to a 90-day transition period if the member provides documentation of that authorization and the service is covered under the Louisiana Blue plan. Providers should submit the previous plan's authorization documentation to request transition coverage.

Louisiana Blue may honor prior plan authorizations for 90 days for the same in‑network benefit
Provider or member must provide prior authorization documentation from previous plan

Note

Coverage Eligibility Clarification

Coverage eligibility statement amended: denials will be issued as not medically necessary when the policy criteria are not met. Providers should review the policy criteria carefully and supply complete documentation to avoid coverage denials.

Coverage eligibility amended to clarify that services not meeting stated criteria are not medically necessary
Ensure complete documentation to support eligibility

Clinical implicationWhen REI meets numeric thresholds in the policy (e.g., ≥15 or ≥5 with symptoms), the patient meets criteria analogous to AHI/RDI thresholds

PAP failure / PAP intolerance — Definitions used in policy

PAP failure definitionPAP failure is usually defined as an AHI greater than 20 events per hour while using PAP

PAP intolerance definitionPAP intolerance = PAP use <4 hours per night for 5 nights or more per week, or refusal to use CPAP

Policy useDocumentation of PAP failure or intolerance is required to consider surgical options when conservative therapy fails

Obstructive sleep apnea (OSA) — Syndrome definition

Syndrome definitionObstructive sleep apnea (OSA) = repetitive episodes of upper airway obstruction due to collapse of the upper airway during sleep

Clinical consequencesOSA causes apneas/hypopneas, daytime sleepiness, cardiovascular sequelae, and increased accident risk

Treatment contextSeverity is commonly expressed using AHI, RDI, or REI and guides selection for CPAP, oral appliances, or surgical interventions per policy criteria

Genio system — Definition and device summary

Device descriptionGenio system = a dual-sided hypoglossal nerve stimulation device implanted to stimulate the hypoglossal nerve and reduce airway collapsibility

Regulatory and evidence contextFDA approval supported by the nonrandomized DREAM trial enrolling 113 patients with coprimary endpoints of AHI and ODI reduction at 12 months

MechanismStimulation produces anterior movement and stiffening of the tongue, dilating the pharynx and reducing obstruction at soft palate and tongue base

RDI / REI — Addition to patient selection criteria

Inclusion in criteriaRespiratory Disturbance Index (RDI) and Respiratory Event Index (REI) were added to the patient selection criteria to further define clinically significant OSA

Role alongside AHIRDI and REI are treated equivalently to AHI in the policy's numeric thresholds (e.g., ≥15 or ≥5 with symptoms) for eligibility determinations

Policy historyAddition of RDI and REI was made in prior policy updates to clarify selection criteria for adults and pediatrics